ENTA - Enanta Pharmaceuticals to Present Data for EDP-938 its Oral Once-Daily N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus at IDWeek(TM) 2023

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-938, its oral, once-daily, N-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek 2023 being held October 11 - 15, 2023 at the Boston Convention and Exhibition Center in Boston, MA.

Date : Thursday, October 12, 2023
Time : 12:15 - 1:30 PM ET
Abstract Number : 923
Poster Title : “EDP-938, A Respiratory Syncytial Virus Antiviral, Demonstrates a High Barrier to Resistance in a Human Challenge Study”
Session Title : Virology: Treatment and Prevention of Viral Infections
Location : Boston Convention and Exhibition Center Poster Hall
Presenter: Rachel Levene, Ph.D.

Further information about IDWeek 2023 can be found here .

About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET ^® (U.S.) and MAVIRET ^® .

View source version on businesswire.com: https://www.businesswire.com/news/home/20230907333204/en/

Media and Investors Contact
Jennifer Viera
617-744-3848
jviera@enanta.com